Positive EMA Opinion for Neurizon’s NUZ-001
Highlights:
- Notice received from the European Medicines Agency for Orphan Medicinal Product Designation of NUZ-001 for ALS treatment.
- This Orphan Designation ensures 10 years of exclusivity in Europe upon approval, granting numerous regulatory advantages.
- Neurizon is poised to expedite the development of NUZ-001 to aid ALS patients facing neurological challenges.
Neurizon Therapeutics Limited (ASX: NUZ & NUZOA), a pioneering biotech company focused on neurodegenerative diseases, has achieved a significant milestone by securing positive feedback from the European Medicines Agency (EMA) regarding the Orphan Medicinal Product Designation (OMPD) for its primary drug candidate NUZ-001, aimed at treating Amyotrophic Lateral Sclerosis (ALS). An official decision from the European Commission on this designation is anticipated soon.
The Orphan Medicinal Product Designation is a critical asset, offering Neurizon valuable incentives such as reduced regulatory fees and expedited assistance during the approval process. Notably, this designation provides a 10-year market exclusivity in the European Union, ensuring no other similar product can gain approval within this time frame in the same therapeutic area.
Neurizon is set to embark on a Phase 2/3 clinical trial as part of the HEALEY ALS Platform Trial, with patient recruitment slated to begin early in the upcoming year. The study protocol is crafted to enhance the potential for early regulatory approval. The positive EMA opinion bolsters the anticipated path for NUZ-001, demonstrating its ability to address significant unmet medical needs in ALS globally.
Dr. Michael Thurn, Managing Director and CEO, stated, "This positive EMA opinion for Orphan Medicinal Product Designation represents a pivotal achievement for Neurizon. The prevalence of ALS in Europe surpasses that in other regions, underscoring the importance of our efforts. With this designation, alongside support from the U.S. FDA, we are establishing a firm market presence for NUZ-001 in key regions, positioning it as a vital treatment option for ALS patients. We are eager to continue our discussions with the EMA and global regulators as we aim to bring this innovative solution to those in need."
Next Steps for Neurizon:
- A final ruling from the European Commission is expected soon.
- Ongoing dialogue with the EMA and U.S. FDA to advance the clinical program for NUZ-001.
- Finalize all preparations for the upcoming Phase 2/3 study within the HEALEY ALS Platform Trial, aligning with the company’s core mission related to neurodegenerative diseases.
-ENDS-
This announcement was approved for release by the Board of Neurizon Therapeutics Limited.
For further information, please contact:
Dr. Michael Thurn
Managing Director and Chief Executive Officer
Neurizon Therapeutics Limited
+61 (3) 9692 7222
About Neurizon Therapeutics Limited
Neurizon Therapeutics Limited (ASX: NUZ) is a biotechnology company focused on developing innovative treatments for neurodegenerative disorders. With NUZ-001 targeting ALS, Neurizon aims to provide effective treatment options while pursuing the drug's potential application in various other neurodegenerative conditions. Committed to collaboration and robust clinical strategies, Neurizon aspires to revolutionize care for individuals affected by these challenging diseases.
Frequently Asked Questions
What is NUZ-001?
NUZ-001 is Neurizon Therapeutics' lead drug candidate being developed for the treatment of ALS, a serious neurodegenerative disorder.
What does the Orphan Medicinal Product Designation mean?
This designation provides benefits like reduced fees and a market exclusivity period, encouraging the development of treatments for rare conditions.
What clinical phase is NUZ-001 currently in?
NUZ-001 is entering a Phase 2/3 clinical trial, aiming for early regulatory approval and patient enrollment expected to begin soon.
How long is the market exclusivity granted by OMPD?
Orphan Designation provides a market exclusivity period of 10 years, preventing similar products from being approved during this time in Europe.
Who leads Neurizon Therapeutics?
Dr. Michael Thurn serves as the Managing Director and Chief Executive Officer of Neurizon Therapeutics Limited.
